SARS-CoV-2 infection leads to vastly divergent clinical outcomes ranging from
asymptomatic infection to fatal disease. Co-morbidities, sex, age, host genetics and vaccine …

The pathogenesis of SARS-CoV-2 in the context of a specific immunological niche is not
fully understood. Here, we used a golden Syrian hamster model to systematically evaluate …

Clinical presentations that develop in response to infection result from interactions between
the pathogen and host defenses. SARS-CoV-2, the etiologic agent of COVID-19, directly …

Some patients infected with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-
2) develop severe pneumonia and the acute respiratory distress syndrome (ARDS). Distinct …

Immune responses to respiratory viruses like SARS-CoV-2 originate and function in the
lung, yet assessments of human immunity are often limited to blood. Here, we conducted …

The interferon response is a potent antiviral defense mechanism, but its effectiveness
depends on its timing relative to viral replication. Here, we report viral replication and host …

Due to the limitation of human studies with respect to individual difference or the
accessibility of fresh tissue samples, how severe acute respiratory syndrome coronavirus 2 …

Initial replication of SARS-CoV-2 in the upper respiratory tract is required to establish
infection, and the replication level correlates with the likelihood of viral transmission. Here …

The variable etiology of persistent breathlessness after COVID-19 have confounded efforts
to decipher the immunopathology of lung sequelae. Here, we analyzed hundreds of cellular …

Patients with chronic lung disease (CLD) have an increased risk for severe coronavirus
disease-19 (COVID-19) and poor outcomes. Here, we analyze the transcriptomes of …